Cash Flow from Financial Activities: The net amount of cash transactions used in funding activities.
Recursion Pharmaceuticals, Inc. (RXRX) had Cash Flow from Financial Activities of $521.53M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$74.68M |
|
$-644.76M |
|
$70.95M |
|
$3.73M |
|
$722.81M |
|
$-648.13M |
|
$3.24M |
|
$-644.89M |
|
$-644.89M |
|
$-644.76M |
|
$-644.76M |
|
$-644.76M |
|
$-644.76M |
|
$-648.13M |
|
$-564.43M |
|
447.45M |
|
447.45M |
|
$-1.44 |
|
$-1.44 |
|
| Balance Sheet Financials | |
$812.85M |
|
$103.93M |
|
$661.28M |
|
$1.47B |
|
$147.71M |
|
$9.56M |
|
$195.56M |
|
$343.26M |
|
$1.13B |
|
$658.80M |
|
$1.13B |
|
528.18M |
|
| Cash Flow Statement Financials | |
$-371.81M |
|
$-16.87M |
|
|
Cash Flow from Financial Activities |
$521.53M |
$603.02M |
|
$753.92M |
|
$150.90M |
|
$111.22M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.50 |
|
-- |
|
-- |
|
0.01 |
|
0.01 |
|
4.99% |
|
-867.87% |
|
-867.87% |
|
-755.79% |
|
-863.53% |
|
-863.35% |
|
$-378.28M |
|
-- |
|
-- |
|
-- |
|
0.05 |
|
-- |
|
3.03 |
|
120.47 |
|
-57.01% |
|
-97.87% |
|
-43.74% |
|
-56.54% |
|
$2.14 |
|
$-0.85 |
|
$-0.83 |
|